Porsolt is thrilled to already have our third paper published for this year: “Anti-CTLA-4 and anti-PD-1 immunotherapies repress tumor progression in preclinical breast and colon model with independent regulatory T cells response”. This will appear in the upcoming June issue of “Translational Oncology”.
The paper highlights the differential effects of immunotherapy treatments, on the tumor immune microenvironment in syngeneic in vivo models of Triple-Negative Breast Cancer (TNBC) and Colorectal Cancer. We demonstrated that anti-CTLA-4 and anti-PD-1 antibodies displayed effective anticancer activity on primary tumors, which was further enhanced when used in combination in the TNBC model. We also demonstrated that blocking CTLA-4 reduced metastasis formation in a pure Colon Cancer metastasis model. In addition, using cytometry-based multiplex analysis, we showed that both anti-CTLA-4 and anti-PD-1 enhanced intratumoral CD8+ T cells while only anti-CTLA-4 reduced regulatory T cells in the tumor microenvironment.
https://lnkd.in/dQ8aJqdt
Contact us to learn more about our capabilities and areas of expertise.
contact@porsolt.com
www.porsolt.com
